Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
361-380 of 1,782 trials

Spironolactone for Arrhythmogenic Right Ventricular Dysplasia (ARVD)

We are studying whether spironolactone can help reduce heart deterioration and arrhythmias in patients with ARVD. This trial compares its effects to a placebo over one and three years.

Arrhythmogenic Right Ventricular Dysplasia>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesCardiologyInternal Medicine

Multiple Myeloma: HyQvia for Infection Prevention

We are studying whether HyQvia can help reduce infections in patients with newly diagnosed multiple myeloma who are not eligible for a transplant. The trial aims to see if it improves survival and quality of life compared to standard care.

Multiple Myeloma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHematologyInfectious Diseases

Lung Cancer Treatment Comparison: Atezolizumab vs. Pembrolizumab

We are studying two treatment combinations for patients with metastatic TTF-1 negative lung adenocarcinoma to see which one may improve survival. This trial compares atezolizumab with carboplatin and nab-paclitaxel against pembrolizumab with platinum and pemetrexed.

Metastatic Lung Adenocarcinoma>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOncologyPulmonology

Juvenile Idiopathic Arthritis: Upadacitinib Study

We are evaluating the safety and how the body processes upadacitinib in children with polyarticular course juvenile idiopathic arthritis. The study also examines how well children tolerate the medication and its taste.

Juvenile Idiopathic Arthritis>2 yearsSafety phase (I)Post-Trial Drug AccessNo PlaceboStandard MedicinesPediatricsRheumatology

Extrapulmonary Small Cell Carcinoma: Durvalumab Combination Therapy

We are studying a new treatment combining durvalumab with carboplatin or cisplatin and etoposide for patients with extensive stage extrapulmonary small cell carcinoma. The goal is to see if this combination improves survival and quality of life compared to standard treatments.

Extensive Stage Extrapulmonary Small Cell CarcinomaEfficacy phase (II)No PlaceboStandard MedicinesOncology

UDCA for Visual Recovery After Retinal Detachment Surgery

We are studying whether UDCA can improve vision recovery in patients who have had surgery for retinal detachment. The trial also looks at the treatment's safety and other effectiveness measures.

Rhegmatogenous Retinal Detachment≤3 monthsConfirmation phase (III)Standard MedicinesOphthalmology

Tocilizumab for Acute Chest Syndrome in Sickle Cell Disease

We are studying whether tocilizumab can help patients with sickle cell disease recover from acute chest syndrome faster and safely. The trial includes both children and adults to assess its effectiveness and safety.

Sickle Cell Disease>2 yearsConfirmation phase (III)Standard MedicinesHematologyPulmonology

Uveitis Treatment: Adalimumab vs. Mycophenolate Mofetil

We are studying whether adalimumab can improve outcomes for people with steroid-dependent non-infectious uveitis compared to the standard treatment. This trial will help us understand the effectiveness and safety of both medications.

Uveitis>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementOphthalmologyRheumatology

Cholestyramine for Obese Women: Pollutant Levels Study

We are exploring how cholestyramine treatment impacts harmful pollutant levels in obese women who may undergo bariatric surgery. This study aims to understand its effects before and after the surgery.

Epidermolysis Bullosa≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesDermatologyEndocrinologyInternal Medicine

IVF Luteal Phase Support: GnRH Agonist vs. hCG

We are studying whether a GnRH agonist can improve live birth rates and reduce miscarriages in women undergoing IVF compared to traditional hCG and progesterone support.

Assisted Reproductive Technology≤3 monthsConfirmation phase (III)No PlaceboStandard MedicinesGynecology and Obstetrics

Childhood Onset Nephrotic Syndrome: Obinutuzumab vs. MMF

We are studying whether obinutuzumab is more effective and safer than MMF for children with childhood onset idiopathic nephrotic syndrome. We will also look at how these treatments affect fatigue and quality of life.

Childhood Idiopathic Nephrotic Syndrome1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNephrology

S. aureus Bacteremia: Cloxacillin Dosing Study

We are investigating whether kidney function can help identify patients who may need adjusted doses of cloxacillin. This study aims to ensure safer and more effective treatment for those with S. aureus bacteremia.

Staphylococcus aureus BacteremiaMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesNephrology

Pyridoxine for Primary Sclerosing Cholangitis

We are studying whether pyridoxine can lower liver enzyme levels in people with primary sclerosing cholangitis. The trial will also look at its effects on vitamin B6 levels, liver function, and quality of life.

Primary Sclerosing Cholangitis≤3 monthsEfficacy phase (II)Standard MedicinesGastroenterologyHepatology

Non-Small Cell Lung Cancer: Fianlimab and Cemiplimab with Chemotherapy

We are studying if adding Fianlimab to Cemiplimab and chemotherapy is safer and more effective for adults with early-stage non-small cell lung cancer that can be surgically removed. This trial will help us understand the best treatment options for these patients.

Resectable Non-small Cell Lung Cancer>2 yearsEfficacy phase (II)16-20 visitsStandard MedicinesCost ReimbursementPartially RemoteOncology

Colon Cancer Treatment: Neo-Adjuvant Chemotherapy for Seniors

We are studying whether a 6-week chemotherapy treatment before surgery helps older adults with resectable colon cancer live longer and stay disease-free. This trial aims to personalize treatment for patients aged 70 and older.

Colon Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Blood Pressure Response: Multi-Omics Study

We are exploring how specific biomarkers can predict the effectiveness of blood pressure medications for individuals. This study aims to improve treatment personalization and understand potential side effects.

Essential Hypertension3-6 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementCardiologyInternal Medicine

COPD Treatment: Understanding ICS Response

We are studying how different eosinophil levels affect the response to inhaled corticosteroids in COPD patients. This research may help personalize treatment strategies for better management of the disease.

Chronic Obstructive Pulmonary Disease (COPD)1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesAllergologyPulmonology

Heart Health: Adenosine Dose Study

We are investigating how different doses of adenosine affect blood flow in the heart for healthy individuals and patients with coronary artery disease. This study aims to understand if the response varies based on health status.

Chronic Ischemic Heart DiseaseMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Autism Spectrum Disorder: Sensorimotor Therapy and Oxytocin

We are exploring whether a new therapy combined with a single dose of oxytocin can improve social connections in children with autism. The goal is to see if this approach enhances their interactions with others.

Autism Spectrum Disorder>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesCost ReimbursementPsychiatry

Osteoarthritis in the Thumb: Comparing Treatments

We are studying whether steroid injections are more effective than saline injections and occupational therapy for painful thumb osteoarthritis. The goal is to improve pain, function, and overall quality of life.

Osteoarthritis of the Thumb>2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesOrthopedics and TraumatologyRheumatology